Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC

Blood (2022) 140 (5): 419–437.

https://doi.org/10.1182/blood.2021012057

Published: 2022

Journal Articles

Primary cytotoxic T-cell lymphomas harbor recurrent targetable alterations in the JAK-STAT pathway

Blood (2021) 138 (23): 2435–2440.

https://doi.org/10.1182/blood.2021012536

Published: 2021

Includes: Supplemental data

Journal Articles

Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides or Sezary Syndrome: Final Results Show Significant Clinical Activity and Suggest Correlation with CD30 Expression

Youn H. Kim, MD, Mahkam Tavallaee, MD MPH, Sima Rozati, MD, Uma Sundram, MD PhD, Katrin Salva, MD, Gary S. Wood, MD, Shufeng Li, MS, Michael Krathen, MD, Seema Nagpal, MD, Sunil Reddy, MD, Randall Armstrong, Richard T. Hoppe, MD, Melissa Pulitzer, MD, Ranjana H Advani, MD, Steven M. Horwitz, MD

Blood (2014) 124 (21): 804.

https://doi.org/10.1182/blood.V124.21.804.804

Published: 2014

Journal Articles

A Cutaneous Lymphoma International Consortium ‘CLIC’ study of Prognostic Parameters in Advanced Stages of Mycosis Fungoides and Sezary Syndrome: Progress Towards Establishing a Prognostic Index to Augment Clinical Staging

Julia J Scarisbrick, MBhons ChB FRCP MD, Pietro Quaglino, Maarten Vermeer, Sean Whittaker, Gary S. Wood, MD, Madeleine Duvic, MD, Miles Prince, MD FRACP, FRCPA, Steven M. Horwitz, MD, Richard T. Hoppe, MD, Pierluigi Porcu, MD, Rudolf Stadler, MD, Felicity Evison, Youn H Kim, MD

Blood (2014) 124 (21): 1621.

https://doi.org/10.1182/blood.V124.21.1621.1621

Published: 2014

Journal Articles

Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event

Mitul D. Gandhi, Andrew M. Evens, Timothy S. Fenske, Paul Hamlin, Bertrand Coiffier, Andreas Engert, Alison J. Moskowitz, Nilanjan Ghosh, Adam M. Petrich, Jon Lomasney, Amy Chadburn, Gary S. Wood, Katrin Salva, Beatrice Nardone, Steven M. Trifilio, Dennis W. Raisch, Dennis P. West, Leo I. Gordon, Jane N. Winter

Blood (2014) 123 (18): 2895–2897.

https://doi.org/10.1182/blood-2014-03-561878

Published: 2014

Journal Articles

Pancreatitis In Patients Treated With Brentuximab Vedotin: A Previously Unrecognized Serious Adverse Event

Mitul Gandhi, MD, Andrew M Evens, DO, MSc, Timothy S. Fenske, MD, Paul Hamlin, MD, Bertrand Coiffier, MD, PhD, Andreas Engert, MD, Alison J. Moskowitz, MD, Nilanjan Ghosh, MD, PhD, Adam M. Petrich, MD, Jon Lomasney, M.D., Amy Chadburn, M.D., Gary S. Wood, MD, Katrin Salva, M.D., Steven M Trifilio, BS Pharm, Dennis W. Raisch, PhD, MS, RPh, Dennis West, PhD, Leo I. Gordon, MD, Jane N. Winter, MD

Blood (2013) 122 (21): 4380.

https://doi.org/10.1182/blood.V122.21.4380.4380

Published: 2013

Journal Articles

Brentuximab Vedotin Demonstrates Significant Clinical Activity in Relapsed or Refractory Mycosis Fungoides with Variable CD30 Expression

Michael Krathen, MD, Uma Sundram, MD, PhD, Sameer Bashey, MD, Katherine Sutherland, C-PA, Katrin Salva, MD, Gary S Wood, MD, Ranjana H. Advani, MD, Richard T. Hoppe, MD, Sunil Reddy, MD, Randall Armstrong, Seema Nagpal, MD, Melissa Pulitzer, MD, Steven M. Horwitz, MD, Youn H. Kim, MD

Blood (2012) 120 (21): 797.

https://doi.org/10.1182/blood.V120.21.797.797

Published: 2012

Journal Articles

Interleukin-12 Therapy of Cutaneous T-Cell Lymphoma Induces Lesion Regression and Cytotoxic T-Cell Responses

Alain H. Rook, Gary S. Wood, Elisa K. Yoo, Rosalie Elenitsas, David M.F. Kao, Matthew L. Sherman, William K. Witmer, Kenneth A. Rockwell, Ryan B. Shane, Stuart R. Lessin, Eric C. Vonderheid

Blood (1999) 94 (3): 902–908.

https://doi.org/10.1182/blood.V94.3.902.415k23_902_908

Published: 1999

NARROW

Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC

Primary cytotoxic T-cell lymphomas harbor recurrent targetable alterations in the JAK-STAT pathway

Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides or Sezary Syndrome: Final Results Show Significant Clinical Activity and Suggest Correlation with CD30 Expression

A Cutaneous Lymphoma International Consortium ‘CLIC’ study of Prognostic Parameters in Advanced Stages of Mycosis Fungoides and Sezary Syndrome: Progress Towards Establishing a Prognostic Index to Augment Clinical Staging

Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event

Pancreatitis In Patients Treated With Brentuximab Vedotin: A Previously Unrecognized Serious Adverse Event

Brentuximab Vedotin Demonstrates Significant Clinical Activity in Relapsed or Refractory Mycosis Fungoides with Variable CD30 Expression

Interleukin-12 Therapy of Cutaneous T-Cell Lymphoma Induces Lesion Regression and Cytotoxic T-Cell Responses

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only